Condition
Isolated Systolic Hypertension
Total Trials
6
Recruiting
0
Active
0
Completed
3
Success Rate
60.0%-27% vs avg
Key Insights
Highlights
Success Rate
60% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 55/100
Termination Rate
33.3%
2 terminated out of 6 trials
Success Rate
60.0%
-26.5% vs benchmark
Late-Stage Pipeline
33%
2 trials in Phase 3/4
Results Transparency
67%
2 of 3 completed with results
Key Signals
2 with results60% success
Data Visualizations
Phase Distribution
6Total
P 1 (1)
P 2 (3)
P 3 (1)
P 4 (1)
Trial Status
Completed3
Terminated2
Unknown1
Trial Success Rate
60.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (6)
Showing 6 of 6 trials
NCT00751829Phase 3CompletedPrimary
Isolated Systolic Hypertension in the Elderly and Very Elderly
NCT05165251Phase 4UnknownPrimary
Blood Pressure and Lipids Reduction in High Risk Elderly Patients With Isolated Systolic Hypertension
NCT01656408Phase 1Completed
A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8150 (MK-8150-002)
NCT00802893Phase 2TerminatedPrimary
Oral 6R-BH4 for the Treatment of Isolated Systolic Hypertension and Endothelial Dysfunction
NCT02088450Phase 2TerminatedPrimary
Systolic Hypertension in Europe Placebo-Controlled Trial
NCT01987284Phase 2CompletedPrimary
SER100 in Isolated Systolic Hypertension
Showing all 6 trials